On January 29, 2018 -Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, reported that three abstracts highlighting the Company’s Listeria-based immunotherapy in combination with antibody-based immunotherapies have been accepted for poster presentation at the upcoming 2018 Keystone Symposia on Cancer Immunotherapies: Combinations (C5) taking place March 23-27, 2018 at the Queen Elizabeth Fairmont in Montreal (Press release, Advaxis, JAN 29, 2018, View Source [SID1234523606]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title:
"Agonism of the CD137 co-stimulatory pathway synergizes with the Listeria monocytogenes-based immunotherapy, axalimogene filolisbac, to promote durable tumor regression in a murine HPV+ tumor model"
Poster Number:
2001
Session:
Poster Session 2
Date:
March 25, 2018
Presenter:
Rachelle E. Kosoff, Ph.D., Senior Scientist, Advaxis, Inc.
Title:
"Combination TIGIT blockade with Listeria-based immunotherapy enhances antigen-specific antitumor immunity"
Poster Number:
3015
Session:
Poster Session 2
Date:
March 25, 2018
Presenter:
Daniel O. Villarreal, Ph.D., Principal Scientist, Advaxis, Inc.
Title:
"Targeting of CCR8 induces antitumor activity as a monotherapy that is further enhanced in combination with a Listeria-based immunotherapy"
Poster Number:
3037
Session:
Poster Session 2
Date:
March 25, 2018
Presenter:
Daniel O. Villarreal, Ph.D., Principal Scientist, Advaxis, Inc.
"We are delighted to present these promising data before an audience of researchers and clinicians dedicated to elucidating the best possible combinations of targeted immunotherapies, to develop better treatments for patients with cancer. The data being presented highlight encouraging preclinical results, which show synergistic effects of a variety of antibody-based immunotherapies with our Lm Technology platform," said Robert G. Petit, Ph.D., Executive Vice President and Chief Scientific Officer of Advaxis.